PLSE
Pulse Biosciences, Inc.
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$53.24
−2.69%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.2M | 350.0K | — | — | 700.0K |
| Cost of Revenue | 1.4M | 1.6M | — | 1.2M | 11.9M |
| Gross Profit | (256.0K) | (1.3M) | — | (1.2M) | (11.2M) |
| Operating Expenses | |||||
| R&D Expense | 51.9M | 44.7M | 32.3M | 27.8M | 20.8M |
| SG&A Expense | 30.9M | 32.0M | 23.9M | 15.8M | 26.0M |
| General & Admin Expense | 15.0M | — | 23.9M | 15.8M | 14.0M |
| Selling & Marketing Expense | — | — | — | — | 12.0M |
| Other Expenses | — | (1.1M) | — | (1.2M) | — |
| Total Operating Expenses | 82.8M | 75.7M | 56.3M | 42.4M | 46.8M |
| Cost and Expenses | 84.2M | 77.3M | 56.3M | 43.6M | 58.8M |
| Operating Income (EBIT) | (83.0M) | (76.9M) | (56.3M) | (43.6M) | (58.1M) |
| Non-Operating | |||||
| Interest Income | 3.0M | 4.2M | 2.7M | 2.5M | — |
| Interest Expense | — | — | — | 1.1M | 448.0K |
| Net Interest Income | 3.0M | 4.2M | 2.7M | 1.4M | (448.0K) |
| Other Non-Op Income/Expense | 3.0M | 4.2M | 2.7M | 1.4M | (448.0K) |
| Non-Operating Income (excl Interest) | (2.4M) | (4.2M) | (2.7M) | (2.5M) | 448.0K |
| EBT (Pre-Tax Income) | (80.1M) | (72.8M) | (53.6M) | (42.2M) | (58.5M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (80.1M) | (72.8M) | (53.6M) | (42.2M) | (58.5M) |
| Earnings from Cont. Ops | (80.1M) | (72.8M) | (53.6M) | (42.2M) | (58.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (80.1M) | (72.8M) | (53.6M) | (42.2M) | (58.5M) |
| Per Share | |||||
| Basic EPS | ($1.17) | ($1.08) | ($0.92) | ($0.88) | ($1.72) |
| Diluted EPS | ($1.17) | ($1.08) | ($0.92) | ($0.88) | ($1.72) |
| Revenue Per Share | $0.02 | $0.01 | $0.00 | $0.00 | $0.02 |
| Shares | |||||
| Basic Shares Outstanding | 69.2M | 67.4M | 58.4M | 48.0M | 33.9M |
| Diluted Shares Outstanding | 69.2M | 67.4M | 58.4M | 48.0M | 33.9M |
| Profitability Metrics | |||||
| EBITDA | (79.9M) | (71.7M) | (52.4M) | (39.9M) | (57.1M) |
| D&A | 770.0K | 1.1M | 1.2M | 1.2M | 1.4M |
| EBIT | (80.6M) | (72.8M) | (53.6M) | (41.1M) | (58.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026